SCHEMBL159163

SCHEMBL159163

OC(=S)NCCc1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.76
RAB9A P51151 4/20 0.76
SMN1; SMN2 Q16637 2/20 0.76
CA12 O43570 2/20 0.68
CA2 P00918 2/20 0.68
CA9 Q16790 2/20 0.68
CA1 P00915 1/20 0.68
LMNA P02545 3/20 0.66
GAA P10253 2/20 0.66
TAAR1 Q96RJ0 1/20 0.66
IDO1 P14902 1/20 0.63
MAOA P21397 1/20 0.63
MAOB P27338 1/20 0.63
PLAAT5 Q96KN8 1/20 0.58
PLAAT4 Q9UL19 1/20 0.58
MEN1 O00255 3/20 0.58
MAPT P10636 3/20 0.58
KMT2A Q03164 3/20 0.58
ALDH1A1 P00352 3/20 0.58
ALOX12 P18054 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4020005 0.94 NPC1 (0.68) NPC1RAB9ASMN1; SMN2CA12CA2
Methane SCHEMBL8530831 0.92 NPC1 (0.66) NPC1RAB9ASMN1; SMN2CA12CA2
Methane SCHEMBL2796518 0.92 NPC1 (0.66) NPC1RAB9ASMN1; SMN2CA12CA2
SCHEMBL11746910 0.92 NPC1 (0.66) NPC1RAB9ASMN1; SMN2CA12CA2
SCHEMBL28883056 0.90 NPC1 (0.63) NPC1RAB9ASMN1; SMN2CA12CA2
SCHEMBL156779 0.87 KMT2A (0.66) NPC1RAB9ASMN1; SMN2LMNAGAA
SCHEMBL6524477 0.86 RAB9A (1.00) NPC1RAB9ASMN1; SMN2CA12CA2
SCHEMBL15550723 0.83 HDAC3 (0.68) CA12CA2CA9CA1LMNA
SCHEMBL4019998 0.83 NPC1 (0.70) NPC1RAB9ASMN1; SMN2CA12CA2
SCHEMBL1860288 0.83 NPC1 (0.70) NPC1RAB9ASMN1; SMN2CA12CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1771162-B1 CAPSAICIN INHIBITORS FOR THE TREATMENT OF OBESITY-RELATED DISORDERS XENIA PHARMA (DK) 2013-06-05 EP claimed
US-8455504-B2 Inhibition of the activity of the capsaicin receptor in the treatment of type 1 diabetes, type 2 diabetes, impaired glucose tolerance or insulin resistance XENIA PHARMA (DK) 2013-06-04 US claimed
EP-4653434-A1 CRYSTALLINE SALT OF MACROPA-(OCH2CH2)-PH-NCS Bayer Aktiengesellschaft (DE) 2025-11-26 EP disclosed
US-9918473-B2 Use of aryl carbamates in agriculture and other plant-related areas North Carolian State University (US) 2018-03-20 US disclosed
US-20160353739-A1 USE OF ARYL CARBAMATES IN AGRICULTURE AND OTHER PLANT-RELATED AREAS UNIV NORTH CAROLINA STATE (US) 2016-12-08 US disclosed
US-9439436-B2 Use of aryl carbamates in agriculture and other plant-related areas NORTH CAROLINA STATE UNIVERSITY (US) 2016-09-13 US disclosed
US-20150327552-A1 USE OF ARYL CARBAMATES IN AGRICULTURE AND OTHER PLANT-RELATED AREAS UNIV NORTH CAROLINA STATE (US) 2015-11-19 US disclosed
US-9125408-B2 Use of aryl carbamates in agriculture and other plant-related areas NORTH CAROLINA STATE UNIVERSITY (US) 2015-09-08 US disclosed
US-8884022-B2 Inhibition of bacterial biofilms with aryl carbamates NORTH CAROLINA STATE UNIVERSITY (US) 2014-11-11 US disclosed
US-20130172187-A1 USE OF ARYL CARBAMATES IN AGRICULTURE AND OTHER PLANT-RELATED AREAS NORTH CAROLINA STATE UNIVERSITY 2013-07-04 US disclosed
EP-1771162-B1 CAPSAICIN INHIBITORS FOR THE TREATMENT OF OBESITY-RELATED DISORDERS XENIA PHARMA (DK) 2013-06-05 EP disclosed
EP-1771162-A2 CAPSAICIN INHIBITORS FOR TREATING OBESITY AND RELATED DISORDERS NOVO NORDISK A/S (DK) 2007-04-11 EP disclosed
US-20060264480-A1 Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same SUH YOUNG G 2006-11-23 US disclosed
WO-2006007851-A2 CAPSAICIN INHIBITORS FOR TREATING OBESITY AND-RELATED DISORDERS NOVO NORDISK A/S (DK) 2006-01-26 WO disclosed
EP-1311477-A4 NOVEL THIOCARBAMIC ACID DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME PACIFIC CORP (KR) 2005-01-12 EP disclosed
US-20030203944-A1 Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same PACIFIC CORPORATION (KR) 2003-10-30 US disclosed
EP-1311477-A1 NOVEL THIOCARBAMIC ACID DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME PACIFIC CORPORATION (KR) 2003-05-21 EP disclosed
WO-2002016317-A1 NOVEL THIOCARBAMIC ACID DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME PACIFIC CORPORATION (KR) 2002-02-28 WO disclosed
US-5637731-A CHOLINERGIC AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1997-06-10 US disclosed
US-5550257-A TREATING CENTRAL CHOLINERGIC DYSFUNCTION AMERICAN CYANAMID COMPANY (US) 1996-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172187-A1 USE OF ARYL CARBAMATES IN AGRICULTURE AND OTHER PLANT-RELATED AREAS CTRC, ACE, DDT NPC1 2027/4885RAB9A 1963/4885SMN1; SMN2 4442/4885
US-20160353739-A1 USE OF ARYL CARBAMATES IN AGRICULTURE AND OTHER PLANT-RELATED AREAS CTRC, ACE, DDT NPC1 2027/4885RAB9A 1963/4885SMN1; SMN2 4442/4885
US-20060264480-A1 Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same TRPV1, TRPA1, TRPV5 NPC1 2332/4885RAB9A 1122/4885SMN1; SMN2 1555/4885
US-20150327552-A1 USE OF ARYL CARBAMATES IN AGRICULTURE AND OTHER PLANT-RELATED AREAS CTRC, ACE, DDT NPC1 2027/4885RAB9A 1963/4885SMN1; SMN2 4442/4885
US-20030203944-A1 Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same TRPV1, TRPA1, TRPV5 NPC1 2332/4885RAB9A 1122/4885SMN1; SMN2 1555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.